TriNetX partners with UC Health to offer more access to clinical trials

TriNetX, a health research network, has partnered with UC Health, the University of Cincinnati's health system, to expand its network to offer information on clinical trials to larger audience of patients.

UC Health’s clinical data will be accessible to biopharmaceutical researchers through the expanding network for TriNetX’s 57 million patients. Using the network of millions of patients from around the world gives UC the opportunity to conduct multiple clinical trials in its academic health system, help researchers search for patients eligible for their clinical trials and collaborate with other teams of researchers.  

Through the TriNetX system, users can pick out patients using filters based on many different data points and criteria, and the data points can be tracked the healthcare organization the patient is a part of to see if they would like to participant in a clinical trial.

"UC Health is committed to providing the highest level of advanced specialty care and cutting edge treatment options to our patients and community.  As the region's only academic health system, our researchers focus on clinical trials which can provide many patients the best possible options for their care.  The academic difference is what sets us apart," said Christopher Lindsell, PhD, vice president for research at UC Health and associate dean for clinical research at the University of Cincinnati College of Medicine. "This collaboration provides additional possibilities to improve the health of our patients while leading the practice of medicine to provide superlative top-tier treatments to our community and beyond.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.